Open Orphan subsidiary signs €6m contract for respiratory study
Company expects revenues from the contract to be recognised across 2022 and 2023
Source: irishtimes.com
Stay updated with breaking news from Open Orphan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company expects revenues from the contract to be recognised across 2022 and 2023
Open Orphan wins £5m RSV human challenge study contract with European biotechnology company
The Dublin-listed pharmaceutical services company said it expects the contract win will generate revenue across its financial years for 2022 and 2023
CytoReason will provide Poolbeg Pharma with its AI models to analyse human trial data to better understand influenza.
Open Orphan potential catalysts and returns for investors Q&A (LON:ORPH)